

# **SUPPLEMENTAL MATERIAL**

**Table S1. Example search strategy (Embase)**

| #  | Searches  | Results |
|----|---|---------|
| 1  | Epicardial adipose tissue.mp.                             | 1249    |
| 2  | Epicardial fat.mp.  | 1481    |
| 3  | Pericardial adipose tissue.mp                             | 161     |
| 4  | Pericardial fat.mp  | 550     |
| 5  | Vulnerable plaque.mp                                      | 2196    |
| 6  | High risk plaque.mp                                       | 288     |
| 7  | Low attenuation plaque.mp                                 | 101     |
| 8  | Napkin ring.mp  | 94      |
| 9  | Positive remodelling                                      | 125     |
| 10 | Spotty calcification                                      | 170     |
| 11 | Plaque characteristics                                    | 1228    |
| 12 | Plaque composition  | 1734    |
| 13 | Plaque vulnerability                                      | 1745    |
| 14 | Thin cap fibroatheroma                                    | 773     |
| 15 | Necrotic core   | 2091    |
| 16 | Exp intravascular ultrasound/                             | 12695   |
| 17 | Exp optical coherence tomography/                         | 36156   |
| 18 | Exp computer assisted tomography/                         | 778928  |
| 19 | Computed tomography coronary angiography.mp               | 1140    |
| 20 | Cardiac computed tomography.mp                            | 2526    |
| 21 | Exp coronary artery calcium score                         | 3230    |
| 22 | Exp coronary angiography/                                 | 2916    |
| 23 | 1 or 2 or 3 or 4  | 2877    |
| 24 | 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 | 7800    |
| 25 | 16 or 17 or 22  | 51500   |
| 26 | 18 or 19 or 20 or 21                                      | 779979  |
| 27 | 23 and 24 and 25  | 26      |
| 28 | 23 and 24 and 26  | 57      |

**Table S2. Study EAT measurement parameters and HRP definitions**

| Author                        | EAT measure method  | Definition of HRP features   |
|-------------------------------|---|--|
| Lu et al. <sup>1</sup>        | <p><u>EAT definition:</u> fat within pericardial sac.</p> <p><u>Method:</u> Semi-automated.</p> <p><u>Software:</u> Volume Viewer, Siemens Medical Solutions, Germany</p> <p><u>Interval:</u> 1cm</p> <p><u>Superior border:</u> mid-level RPA</p> <p><u>Inferior border:</u> diaphragm</p> <p><u>HU range:</u> -195 to -45 HU</p>  | <p><u>PR:</u> RI of &gt;1.1 maximal outer vessel diameter at plaque divided by average of the proximal and distal normal vessels</p> <p><u>LAP:</u> &lt;30 HU</p> <p><u>SpC:</u> &lt;3mm CP extending &lt;1.5mm long-axis vessel diameter &amp; two-thirds vessel circumference</p> <p><u>NRS:</u> ring of peripheral high attenuation surrounded by core of low attenuation in a non-calcified plaque</p>   |
| Schlett et al. <sup>2</sup>   | <p><u>EAT definition:</u> fat within pericardial sac.</p> <p><u>Method:</u> Manual</p> <p><u>Software:</u> Leonardo, Siemens Medical Solutions</p> <p><u>Interval:</u> 1cm</p> <p><u>Superior border:</u> mid-level RPA.</p> <p><u>Inferior border:</u> not specified.</p> <p><u>HU range:</u> -190 to -30 HU</p>   | <p><u>PR:</u> &gt;1.05 remodelling index</p> <p><u>LAP:</u> &lt;30 HU</p> <p><u>SC:</u> &lt;3mm diameter CP</p> <p>HRP defined as at least 2 characteristics in lesions &gt;50% luminal narrowing</p>  |
| Rajani et al. <sup>3</sup>    | <p><u>EAT definition:</u> fat within pericardial sac.</p> <p><u>Method:</u> Semi-automated</p> <p><u>Software:</u> QFAT, Cedars-Sinai Medical Centre</p> <p><u>Interval:</u> 3mm (total 20-40 slices per pt)</p> <p><u>Superior border:</u> RPA take-off</p> <p><u>Inferior border:</u> First slice where PDA visualised</p> <p><u>HU range:</u> -190 to -30 HU</p>   | <p><u>LAP:</u> &lt;30 HU</p> <p><u>PR:</u> &gt;1.05 (maximal outer arterial wall diameter along plaque exceeding proximal reference by 5%)</p>   |
| Oka et al. <sup>4</sup>       | <p><u>EAT definition:</u> adipose tissue between epicardial surface of myocardium and pericardium</p> <p><u>Method:</u> Manual</p> <p><u>Software:</u> Not specified. VAT measured with Virtual Place, AZE Inc., Japan</p> <p><u>Interval:</u> 1cm</p> <p><u>Superior border:</u> 1cm above left main coronary artery (atrial appendage)</p> <p><u>Inferior border:</u> cardiac apex</p> <p><u>HU range:</u> -250 to -30 HU</p> | <p><u>CT-low density plaque:</u> &lt; 39 HU</p> <p><u>PR:</u> remodelling index &gt;1.05</p> <p><u>SpC:</u> calcium burden length &lt;3/2 vessel diameter and width &lt;2/3 vessel diameter</p>  |
| Ito et al. <sup>5</sup>       | <p><u>EAT definition:</u> adipose tissue within the visceral epicardium</p> <p><u>Method:</u> Manual</p> <p><u>Software:</u> Not specified</p> <p><u>Interval:</u> Not specified. 8-12 slices per patient</p> <p><u>Superior border:</u> Mid left atrium</p> <p><u>Inferior border:</u> left ventricular apex</p> <p><u>HU range:</u> -190 to -30 HU</p>  | <p><u>LAP:</u> &lt;30 HU</p> <p><u>PR:</u> RI &gt;1.1 (ratio of outer vessel area of lesion to outer vessel area of proximal reference site)</p>   |
| Nakanishi et al. <sup>6</sup> | <p><u>EAT definition:</u> adipose tissue within the pericardial sac</p> <p><u>Method:</u> Semi-automated</p> <p><u>Software:</u> Synapse Vincent, Japan</p> <p><u>Interval:</u> not specified. 7-10 planes</p> <p><u>Superior border:</u> bifurcation pulmonary artery</p> <p><u>Inferior border:</u> last slice containing any portion of the heart</p> <p><u>HU range:</u> -250 to -30 HU</p>                                 | <p><u>LAP:</u> &lt;30 HU</p> <p><u>PR:</u> RI &gt;1.1</p>  |
| Ito et al. <sup>7</sup>       | <p><u>EAT definition:</u> adipose tissue within the visceral epicardium</p> <p><u>Method:</u> Manual</p> <p><u>Software:</u> Not specified. CT with Aquarius NetStation, USA</p> <p><u>Interval:</u> not specified.</p> <p><u>Superior border:</u> not specified</p> <p><u>Inferior border:</u> not specified</p> <p><u>HU range:</u> -250 to -40 HU</p>  | <p><u>CT:</u></p> <p><u>LAP:</u> &lt;30 HU</p> <p><u>PR:</u> RI &gt;1.1 (ratio of outer vessel area of lesion to outer area of proximal reference site)</p> <p><u>OCT:</u></p> <p>Necrotic lipid pools quantified as number of quadrants</p> <p>Cap thickness measured at thinnest section of distance from lumen to inner border of lipid pool.</p> <p>TCFA = plaque with necrotic lipid pool in ≥2 quadrants within a plaque and fibrous cap ≤65µm</p> |

|                               |  |   |
|-------------------------------|--|---|
| Park et al. <sup>8</sup>      | <p><u>Method</u>: 2D parasternal long-axis view; point on the free wall of RV to assess anterior echo-lucent space between linear echo-dense parietal pericardium and RV epicardium</p> <p><u>Cardiac cycle timing</u>: End-diastole.</p> <p>Thickest point of EAT in each of 3 cycles measured and average value used</p> | <p>Plaque components:</p> <p><u>Fibrous</u> – areas of dense collagen</p> <p><u>Fibrofatty</u> – fibrous tissue with interspersed lipid in collagen</p> <p><u>Dense calcium</u> – calcium with no adjacent necrosis</p> <p><u>Necrotic core</u> – necrotic regions containing cholesterol clefts, foam cells, microcalcification</p> <p><u>TCFA</u>: necrotic core <math>\geq 10\%</math> plaque area without overlying fibrous tissue and having <math>&gt;40\%</math> plaque burden in 3 consecutive frames</p> |
| Tachibana et al. <sup>9</sup> | <p><u>Method</u>: 2D parasternal long-axis view; point on the free wall of RV along midline of ultrasound beam perpendicular to aortic annulus</p> <p><u>Cardiac cycle timing</u>: End-systole.</p> <p>Average of three cardiac cycles used</p>  | <p><u>PR</u>: <math>RI &gt; 1.05</math> (cross sectional lesion vessel area divided by proximal reference vessel area)</p> <p><u>LAP</u>: <math>&lt; 30</math> HU</p>   |

CT – computed tomography, CP – calcified plaque, EAT – epicardial adipose tissue, HRP – high risk plaque, HU – Hounsfield units, LAP – low attenuation plaque, NRS – napkin ring sign, OCT – optical coherence tomography, PDA – posterior descending artery, PR – positive remodelling, RPA – right pulmonary artery, SpC – spotty calcification, TCFA – thin-cap fibroatheroma. VAT – visceral adipose tissue

**Table S3. Sensitivity analysis displaying pooled odds ratios and 95% confidence intervals with systematic exclusion of individual studies.**

| <b>Excluded study</b>         | <b>Pooled OR</b> | <b>Lower 95% CI</b> | <b>Upper 95% CI</b> | <b><i>I</i><sup>2</sup></b> | <b>p-value</b> |
|-------------------------------|------------------|---------------------|---------------------|-----------------------------|----------------|
| Lu et al. <sup>1</sup>        | 1.27             | 1.12                | 1.45                | 70%                         | <0.001         |
| Schlett et al. <sup>2</sup>   | 1.17             | 1.06                | 1.30                | 80%                         | 0.003          |
| Rajani et al. <sup>3</sup>    | 1.19             | 1.07                | 1.33                | 82%                         | 0.001          |
| Oka et al. <sup>4</sup>       | 1.20             | 1.07                | 1.33                | 82%                         | 0.001          |
| Ito et al. <sup>5</sup>       | 1.24             | 1.08                | 1.43                | 78%                         | 0.003          |
| Nakanishi et al. <sup>6</sup> | 1.24             | 1.09                | 1.42                | 82%                         | 0.002          |
| Park et al. <sup>8</sup>      | 1.25             | 1.09                | 1.43                | 83%                         | 0.001          |
| Ito et al. <sup>7</sup>       | 1.19             | 1.07                | 1.32                | 81%                         | 0.001          |
| Tachibana et al. <sup>9</sup> | 1.16             | 1.06                | 1.27                | 74%                         | 0.001          |

**Table S4. Newcastle-Ottawa Scale (NOS) Evaluation of Study Quality**

| <b>STUDY</b>                  | <b>SELECTION</b> | <b>COMPARABILITY</b> | <b>OUTCOME</b> |
|-------------------------------|------------------|----------------------|----------------|
| Lu et al. <sup>1</sup>        | ****             | **                   | ***            |
| Schlett et al. <sup>2</sup>   | ****             | **                   | ***            |
| Rajani et al. <sup>3</sup>    | *****            | **                   | ***            |
| Oka et al. <sup>4</sup>       | ****             | **                   | ***            |
| Ito et al. <sup>5</sup>       | ****             | **                   | ***            |
| Nakanishi et al. <sup>6</sup> | ***              | **                   | ***            |
| Park et al. <sup>8</sup>      | ****             | **                   | ***            |
| Ito et al. <sup>7</sup>       | ***              | **                   | ***            |
| Tachibana et al. <sup>9</sup> | ****             | **                   | **             |


The Newcastle-Ottawa Scale (NOS) evaluates the included studies based on selection, comparability and outcome. The maximum score for each criteria is 5, 2 and 3, respectively, with the maximum total score equalling 10

**Table S5. GRADE quality assessment**

| <b>STUDY</b>                  | <b>INITIAL GRADE</b> | <b>BIAS ASSESSMENT</b>   | <b>FINAL GRADE</b> |
|-------------------------------|----------------------|--|--------------------|
| Lu et al. <sup>1</sup>        | Low                  | <b>Bias:</b> Low; <b>Applicability:</b> Low; <b>Imprecision:</b> Low             | Low                |
| Schlett et al. <sup>2</sup>   | Low                  | <b>Bias:</b> Low; <b>Applicability:</b> Low; <b>Imprecision:</b> High            | Low                |
| Rajani et al. <sup>3</sup>    | Low                  | <b>Bias:</b> Low; <b>Applicability:</b> Low; <b>Imprecision:</b> Low             | Low                |
| Oka et al. <sup>4</sup>       | Low                  | <b>Bias:</b> Unclear; <b>Applicability:</b> Low; <b>Imprecision:</b> High        | Low                |
| Ito et al. <sup>5</sup>       | Low                  | <b>Bias:</b> Unclear; <b>Applicability:</b> Low; <b>Imprecision:</b> Low         | Low                |
| Nakanishi et al. <sup>6</sup> | Low                  | <b>Bias:</b> Unclear; <b>Applicability:</b> High; <b>Imprecision:</b> Low        | Low                |
| Park et al.                   | Low                  | <b>Bias:</b> Unclear; <b>Applicability:</b> Unclear; <b>Imprecision:</b> Unclear | Low                |
| Ito (2012) et al.             | Low                  | <b>Bias:</b> Unclear; <b>Applicability:</b> Low; <b>Imprecision:</b> Unclear     | Low                |
| Tachibana et al               | Low                  | <b>Bias:</b> High; <b>Applicability:</b> Unclear; <b>Imprecision:</b> High       | Very Low           |

GRADE classification adapted from the GRADE Handbook<sup>10-12</sup> to evaluate quality of evidence in observational studies. All studies are observational and therefore considered of low quality. Assessment based on bias (factors including eligibility criteria, control of confounding), applicability (assessment of intervention) and imprecision (assessment of modelling methods and outcomes). Assessment is graded as either a low risk of bias, high risk of bias or unclear risk of bias.

**Figure S1. Funnel plot**



Egger's test for small study effects:  $p = 0.005$

Overall summary estimate using trim and fill method: 1.13 (95% CI 1.03-1.28,  $p=0.04$ ,  $I^2=81\%$ )



## Supplemental References:

1. Lu MT, Park J, Ghemigian K, Mayrhofer T, Puchner SB, Liu T, Fleg JL, Udelson JE, Truong QA, Ferencik M, Hoffmann U. Epicardial and paracardial adipose tissue volume and attenuation - association with high-risk coronary plaque on computed tomographic angiography in the romicat ii trial. *Atherosclerosis*. 2016;251:47-54.
2. Schlett CL, Ferencik M, Kriegel MF, Bamberg F, Ghoshhajra BB, Joshi SB, Nagurney JT, Fox CS, Truong QA, Hoffmann U. Association of pericardial fat and coronary high-risk lesions as determined by cardiac ct. *Atherosclerosis*. 2012;222:129-134.
3. Rajani R, Shmilovich H, Nakazato R, Nakanishi R, Otaki Y, Cheng VY, Hayes SW, Thomson LE, Friedman JD, Slomka PJ, Min JK, Berman DS, Dey D. Relationship of epicardial fat volume to coronary plaque, severe coronary stenosis, and high-risk coronary plaque features assessed by coronary ct angiography. *J Cardiovasc Comput Tomogr*. 2013;7:125-132.
4. Oka T, Yamamoto H, Ohashi N, Kitagawa T, Kunita E, Utsunomiya H, Yamazato R, Urabe Y, Horiguchi J, Awai K, Kihara Y. Association between epicardial adipose tissue volume and characteristics of non-calcified plaques assessed by coronary computed tomographic angiography. *Int J Cardiol*. 2012;161:45-49.
5. Ito T, Suzuki Y, Ehara M, Matsuo H, Teramoto T, Terashima M, Nasu K, Kinoshita Y, Tsuchikane E, Suzuki T, Kimura G. Impact of epicardial fat volume on coronary artery disease in symptomatic patients with a zero calcium score. *Int J Cardiol*. 2013;167:2852-2858.
6. Nakanishi K, Fukuda S, Tanaka A, Otsuka K, Taguchi H, Yoshikawa J, Shimada K. Epicardial adipose tissue accumulation is associated with renal dysfunction and coronary plaque morphology on multidetector computed tomography. *Circ J*. 2016;80:196-201.
7. Ito T, Nasu K, Terashima M, Ehara M, Kinoshita Y, Ito T, Kimura M, Tanaka N, Habara M, Tsuchikane E, Suzuki T. The impact of epicardial fat volume on coronary plaque vulnerability: Insight from optical coherence tomography analysis. *Eur Heart J Cardiovasc Imaging*. 2012;13:408-415.
8. Park JS, Choi SY, Zheng M, Yang HM, Lim HS, Choi BJ, Yoon MH, Hwang GS, Tahk SJ, Shin JH. Epicardial adipose tissue thickness is a predictor for plaque vulnerability in patients with significant coronary artery disease. *Atherosclerosis*. 2013;226:134-139
9. Tachibana M, Miyoshi T, Osawa K, Toh N, Oe H, Nakamura K, Naito T, Sato S, Kanazawa S, Ito H. Measurement of epicardial fat thickness by transthoracic echocardiography for predicting high-risk coronary artery plaques. *Heart Vessels*. 2016;31:1758-1766.
10. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW, Jr., Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schunemann HJ. Grade guidelines 6. Rating the quality of evidence--imprecision. *J. Clin. Epidemiol*. 2011;64:1283-1293.
11. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Glasziou P, Jaeschke R, Akl EA, Norris S, Vist G, Dahm P, Shukla VK, Higgins J, Falck-Ytter Y, Schunemann HJ. Grade guidelines: 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol*. 2011;64:1294-1302.

12. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW, Jr., Atkins D, Meerpohl J, Schunemann HJ. Grade guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J. Clin. Epidemiol.* 2011;64:407-415.